Sparks Charisse Y
Known title: DirectorCIK: 0001940873
Sparks Charisse Y's purchase track record
Sparks Charisse Y has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 10/12/2023 | INSP | $15K | +27.5% | +57.0% | +19.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| INSP | ▼ Sell | Gift | 64 | $0 | 5/29/2024 | View on chart |
| INSP | ▲ Buy | Grant | 2,694 | $0 | 2/9/2024 | View on chart |
| INSP | ▲ Buy | Grant | 2 | $652 | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 3 | $451 | 1/16/2024 | View on chart |
| INSP | ▲ Buy | Grant | 25 | $4K | 10/13/2023 | View on chart |
| INSP | ▲ Buy | Open Market | 100 | $15K | 10/12/2023 | View on chart |
| INSP | ▲ Buy | Grant | 40 | $13K | 7/17/2023 | View on chart |
| INSP | ▲ Buy | Grant | 669 | $0 | 4/27/2023 | View on chart |
| INSP | ▲ Buy | Grant | 56 | $13K | 4/10/2023 | View on chart |
| INSP | ▲ Buy | Grant | 52 | $13K | 1/10/2023 | View on chart |
| INSP | ▲ Buy | Grant | 51 | $9K | 10/11/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Barclays Starts Coverage of Inspire Medical with Underweight
Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.
Barclays Starts Coverage of Inspire Medical with Underweight. Barclays has begun coverage of Inspire Medical Systems and assigned an Underweight rating. The firm set a price target of $65 for the stock. This rating follows the recent analyst activity on the company. The stock is currently near its long‑term support level.